| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/15/2023 | 80.33% | Jefferies | $4 → $11 | Upgrades | Hold → Buy |
| 10/26/2023 | 31.15% | Morgan Stanley | $4 → $8 | Upgrades | Underweight → Equal-Weight |
| 08/15/2023 | 80.33% | SVB Securities | $6 → $11 | Maintains | Outperform |
| 08/15/2023 | 63.93% | Guggenheim | $9 → $10 | Maintains | Buy |
| 08/15/2023 | -18.03% | Goldman Sachs | $4.5 → $5 | Maintains | Neutral |
| 07/25/2023 | 145.9% | BMO Capital | $11 → $15 | Maintains | Outperform |
| 06/21/2023 | — | Evercore ISI Group | Initiates Coverage On | → Outperform | |
| 06/12/2023 | 47.54% | Guggenheim | → $9 | Initiates Coverage On | → Buy |
| 05/15/2023 | -26.23% | Goldman Sachs | $4 → $4.5 | Maintains | Neutral |
| 03/17/2023 | -1.64% | SVB Leerink | → $6 | Initiates Coverage On | → Outperform |
| 01/24/2023 | -34.43% | Morgan Stanley | $5 → $4 | Maintains | Underweight |
| 08/12/2022 | -18.03% | Morgan Stanley | $10 → $5 | Downgrades | Overweight → Underweight |
| 08/11/2022 | 80.33% | BMO Capital | $19 → $11 | Maintains | Outperform |
| 08/11/2022 | -34.43% | Goldman Sachs | $5 → $4 | Maintains | Neutral |
| 07/15/2022 | 63.93% | Morgan Stanley | $15 → $10 | Maintains | Overweight |
| 06/17/2022 | 211.48% | BMO Capital | → $19 | Initiates Coverage On | → Outperform |
| 05/24/2022 | 145.9% | Morgan Stanley | $19 → $15 | Maintains | Overweight |
| 05/24/2022 | 31.15% | Goldman Sachs | $12 → $8 | Maintains | Neutral |
| 04/05/2022 | 211.48% | Morgan Stanley | $20 → $19 | Maintains | Overweight |
| 06/23/2021 | 506.56% | Morgan Stanley | → $37 | Initiates Coverage On | → Overweight |
| 06/22/2021 | 588.52% | Goldman Sachs | → $42 | Initiates Coverage On | → Buy |
| 06/22/2021 | 506.56% | Morgan Stanley | → $37 | Initiates Coverage On | → Overweight |
| 06/22/2021 | 473.77% | Jefferies | → $35 | Initiates Coverage On | → Buy |
What is the target price for Centessa Pharmaceuticals (CNTA)?
The latest price target for Centessa Pharmaceuticals (NASDAQ: CNTA) was reported by Jefferies on November 15, 2023. The analyst firm set a price target for $11.00 expecting CNTA to rise to within 12 months (a possible 80.33% upside). 11 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Centessa Pharmaceuticals (CNTA)?
The latest analyst rating for Centessa Pharmaceuticals (NASDAQ: CNTA) was provided by Jefferies, and Centessa Pharmaceuticals upgraded their buy rating.
When is the next analyst rating going to be posted or updated for Centessa Pharmaceuticals (CNTA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Centessa Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Centessa Pharmaceuticals was filed on November 15, 2023 so you should expect the next rating to be made available sometime around November 15, 2024.
Is the Analyst Rating Centessa Pharmaceuticals (CNTA) correct?
While ratings are subjective and will change, the latest Centessa Pharmaceuticals (CNTA) rating was a upgraded with a price target of $4.00 to $11.00. The current price Centessa Pharmaceuticals (CNTA) is trading at is $6.10, which is within the analyst's predicted range.